Last reviewed · How we verify
Kemester (HOMOSALATE)
Homosalate, marketed under the brand name Kemester, is a well-established product in the sunburn prevention market. A key strength of Homosalate is its protected intellectual property, with a key composition patent expiring in 2028, providing a significant barrier to entry for generic competitors. The primary risk facing Homosalate is the eventual loss of patent protection in 2028, which could lead to increased competition and potential revenue erosion.
At a glance
| Generic name | HOMOSALATE |
|---|---|
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | FDA-approved |
Approved indications
- Sunburn Prevention
- Skin Cancer Risk Reduction
- Early Skin Aging Prevention
Common side effects
Key clinical trials
- Assessment of the Human Systemic Absorption of Sunscreen Ingredients (PHASE1)
- Determination of Sun Protection in Sunscreen Formulas (Study SR09-15)(P08236)(COMPLETED) (PHASE3)
- Multi-Centre European Photopatch Test Study (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Kemester CI brief — competitive landscape report
- Kemester updates RSS · CI watch RSS